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Abstract This guideline summarizes the current view of
the European Association of Nuclear Medicine Drug
Development Committee. The purpose of this guideline
is to guarantee a high standard of PET studies that are
aimed at measuring target occupancy in the brain within
the framework of development programs of drugs that act
within the central nervous system (CNS drugs). This
guideline is intended to present information specifically
adapted to European practice. The information provided
should be applied within the context of local conditions
and regulations.
Keywords Drug development . Target occupancy . Positron
emission tomography
Background
Positron emission tomography (PET) is a molecular imaging
tool well suited for in vivo imaging and quantifying receptors,
transporters, and enzymes in the brain that can be potential
targets for CNS drugs. Within drug development programs at
the industrial level, the average cost for a drug to be brought to
the market is approximately US$ 1 billion, and the time need-
ed for the process is typically up to 15 years [1]. In addition,
based on estimates of the US Food and Drug Administration
(FDA), there is less than a 10 % chance for a drug entering
clinical trials to reach the market, often because of lack of
efficacy, undesirable side-effects, or inappropriate kinetics
[2]. In the CNS, despite the presence of several hundreds of
potential targets for new drugs, the functional relevance of
most of the proteins in the human brain is not fully under-
stood, especially in relation to the doses of new drugs.
Inappropriate selection of doses, namely too high or too low
doses, may lead to failure of the drug development in phases 2
and/or 3. Measurement of target occupancy in the brain
in vivo is expected to be useful for an appropriate dose setting.
These guidelines are primarily focused on the use of posi-
tron emission tomography as a molecular imaging tool to in-
vestigate the fraction of the total target population (receptor,
transporter or enzyme, etc.) in the brain that is occupied by a
CNS drug [3].
In these guidelines, we assume that standard stand-alone
PET systems and appropriate PET reconstruction algorithms
are implemented and used for the PET occupancy study.
Regular calibration of the PET systems should be performed
to validate the data acquisition. When PET/CTor PET/MRI is
considered for use, extra cautions for each modality’s charac-
teristics such as radiation from CT and issues of the attenua-
tion and scatter corrections related to MRI should be taken
into consideration. The bias introduced by different PET
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reconstruction algorithms should be also considered before
the study starts. The issues related to validation of the modal-
ities should be checked elsewhere.
We hope that these guidelines would help all researchers
who are interested in the target occupancy study of CNS
drugs, especially to researchers who aim to establish and/or
improve the collaborative PET studies for drug development
between academic sites and pharmaceutical companies.
All preclinical and clinical PET occupancy studies should
have ethical approvals from relevant committees before the
studies start. Clinical studies should follow the declaration of
Helsinki and possibly organize the central recordings of the
PET studies.
Key issues to consider for the PET occupancy study
Selection of appropriate radioligands
The following three criteria are recommended for radioligands
used in PET occupancy studies.
1. High specific binding and selectivity for the target
If the ratio of specific to nonspecific binding is low, the
outcome measures will be less robust. If a radioligand
binds to several targets (i.e., has low selectivity), the oc-
cupancy calcula ted for the test drug may be
underestimated, if the latter is selective for a single target.
If test drug and radioligand both bind competitively to off-
target sites, the occupancy might be calculated incorrectly.
If possible, information on in vitro affinities for both tar-
get and off-target sites should be obtained prior to PET
occupancy studies.
2. Well-established quantitative methods for measuring
radioligand binding
Quantitative methods for measuring radioligand bind-
ing should be established well before PET occupancy
studies. To calculate occupancy, outcome measures of
these methods should preferably reflect specific binding
to the target (e.g., binding potential (BPND) or specific
distribution volume (VS)) [4]. Reversibility and level of
non-displaceable binding of the tracer, together with total
length and framing of the dynamic PET measurement
should be established in advance. Radioligands for which
BPND or VS are difficult to estimate are discussed later in
section E.
3. Low test-retest variability of outcome measures of the
radioligand
Although there is no definite threshold for the test-retest
variability needed for occupancy studies, clearly variability
should be as low as possible. When test-retest variability is
high, more data points are needed for robust characteriza-
tion of the dose-occupancy curve. Apart from the
radioligand itself, test-retest variability depends on several
other factors such as the PET facilities and auxiliary equip-
ment used. In any case, test-retest variability should be
measured prior to or as part of the occupancy study.
Selection of subjects
Experimental animals (nonhuman primates, pigs, rats, etc.)
If experimental animals are available at the local PET facility,
preclinical PET occupancy studies can be considered before
studies in human subjects. Preclinical PET studies should only
be performed in a complimentary and/or bridgingmanner to the
clinical PEToccupancy study, i.e., when full occupancy cannot
be achieved in humans because of safety reasons. It should be
considered that there may be species differences in the kinetic
behaviour and metabolism of the radioligand and the test drug.
Therefore, preclinical studies should be designed in such a way
that they are relevant for the human situation. The choice of
experimental animals is essential in ensuring that results of
occupancy studies can be translated to human subjects.
Although the accessibility to the nonhuman primates (NHP)
is limited in some parts of Europe, non-human primates are
typically considered as a suitablemodel to predict the behaviour
of a drug and a PET radioligand in the human brain.
Human subjects (healthy volunteers, patients), gender
and age
In general, healthy volunteers are appropriate for human PET
occupancy studies, at least in the initial stages of developing a
new drug. If the target density is expected to be variable dur-
ing the menstrual cycle or when other gender factors could
play a role, inclusion/exclusion criteria or the schedule of PET
measurements should be adjusted accordingly. Inclusion/
exclusion criteria of healthy volunteers should be defined for
each PEToccupancy study, considering possible confounding
variables for each target.
Certain drug targets in the brain, e.g., dopamine receptors
are known to decrease with age. Nevertheless, as it can be
considered to be stable during the short time interval of a
PET occupancy study, i.e., within 1–2 months, age effects
on occupancy measurements usually are negligible (for repeat
measurements in the same healthy subjects).
Clearly, if a test drug is intended for a certain age range and/
or gender, e.g., test drugs for dementia, and pharmacokinetic
parameters are expected to depend on age and/or gender, occu-
pancy studies should be performed in the appropriate target
population. In addition, when patients are included in an occu-
pancy study, it is always important to verify whether previous
chronic drug treatment has had any effects on the binding of the
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radioligand to the target (e.g., because of very slow dissociation
from the target or by altering expression of the target).
Designing and scheduling of the study
Preclinical PET occupancy study
At least one baseline PET measurement (i.e., when no test
drug is administered before PET measurement) and one pre-
treatment PET measurement (i.e., the test drug is administered
before PET measurement) should be performed for each ex-
perimental animal. During PET measurements, vital signs,
such as blood pressure, heart rate, ECG, and blood oxygena-
tion should be monitored to evaluate potential side effects. In
principle, even when a preclinical PET occupancy study is
performed in the early phase of drug development, ideally
safety data of the test drug should be available prior to the
PET study, especially in the case of NHP. Although a wide
range of doses for the test drug are investigated in a PET
occupancy study, the highest dose should be lower than the
maximal safe dose. An example PET schedule using NHP, in
which four occupancy data points are obtained in 2 days, is
shown in Fig. 1.
The study design and scheduling of the preclinical PET
occupancy study depends on the following factors:
a. Radioligand synthesis at the facility
– How many times per day can the radioligand be
synthesized?
– How many times per day can the radioligand be
synthesized?
b. Availability of experimental animals
– What is the maximum allowable time per
experiment?
– What is the maximum allowable number of measure-
ments per experimental animal?
– Are studies without anaesthesia possible?
– Type of anaesthesia, i ts interact ion with
radioligand and/or test drug. Preferably in vitro
data about the effects on the radioligand binding
by anesthesia should be available prior to PET
occupancy study.
c. Characteristics of the radioligands
– The half-life of the radionuclide (e.g., C-11 or F-18)
used for labelling, defining the minimum interval be-
tween measurements (at least 5 half-lives).
– Brain kinetics of the radioligand, defining minimum
duration of a PET measurement, e.g., 60 min for
[11C]raclopride (dopamine D2 receptor), and requir-
ing a radionuclide with a suitable half-life.
d. Blood sampling and metabolite analysis
– For many PET radioligands (i.e., all radioligands
without a valid reference region), measurement of
the arterial input function is necessary for
Fig. 1 Example of a schedule of
a PEToccupancy protocol using a
C-11 labelled ligand. Two
nonhuman primates are enrolled
in the study. A total of three PET
measurements, one baseline
measurement followed by two
pretreatment (one at low and one
at higher dose) measurements, are
performed in each nonhuman
primate on the same day. In the
second nonhuman primate, the
drug dose can be adjusted based
on the results of the first (adaptive
design). According to this
schedule, four occupancy data
points can be obtained in 2 days.
If the radioligand is labelled with
F-18, only one PET measurement
can be performed per day due to
the longer half-life and more days
are required to obtain the same
four occupancy data points
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quantitative analysis of occupancy studies, raising
the following issues:
Is arterial sampling feasible?
What is the maximum allowable blood volume that
can be withdrawn (e.g., in repeat measurements)?
Is equipment for metabolite analysis and measure-
ment of protein binding available?
e. Pharmacokinetics of the test drug
– Routes of drug administration, i.e., orally, intrave-
nous or intramuscular?
– In case of intravenous administration, bolus, bolus
plus constant infusion, slow infusion, or acute vs
chronic dosing?
– Time to reach maximal plasma level of the drug
(Tmax) and time at the trough level of the drug
(Ttrough).
– Presence of active metabolites?
– Timing of the pre-treatment PET measurement(s):
aimed for Tmax and/or Ttrough?
– Multiple pre-treatment PET measurements to inves-
tigate the time course of the target occupancy?
– Effects of the test drug on cerebral blood flow. PET
measurements should be performed at the physiolog-
ical steady state, i.e., not when cerebral blood flow
undergoes (rapid) changes due to the test drug.
Clinical PET occupancy study
Safety data of the test drug should be available prior to the
PETstudy. At least one baseline PET measurement (i.e., when
no test drug is administered before PET measurement) and
one pretreatment PET measurement (i.e., the test drug is ad-
ministered before PETmeasurement) should be performed per
subject. Theoretically, the relationship between target occu-
pancy and dose/plasma concentration of the drug can be
established from just a single occupancy data point according
to the law of mass action, provided the drug only interacts
with a single binding site. However, considering the presence
of noise in the PET data, it is advisable to have as many points
as possible to examine the relationship between dose or plas-
ma concentration of the drug and target occupancy. Ideally,
several different doses should be used in order to cover the
entire range from low to high occupancy levels. In addition, to
account for intersubject variability, it is recommended to scan
several subjects with the same dose.
The study design of a clinical PET occupancy study de-
pends on the following factors:
a. Radioligand synthesis at the facility.
– In case of C-11, how many times per day can the
radioligand be synthesized?
b. Radiation dosimetry
– The total number of PET measurements is limited
by the radiation absorbed dose received by the
subjects. Generic dosimetry tables are available
for both 18F and 11C labelled brain tracers, for
adults indicating effective doses of 4.3 (11C) and
28 (18F) μSv/MBq, respectively [5], illustrating
that more repeat studies can be performed using
an 11C labelled tracer. For novel ligands, as it
depends on the kinetics of the radioligands [6,
7], the absorbed dose of individual radioligand
should be investigated. The ICRP has published
absorbed dose constraints for medical exposure
for volunteers in biomedical research, depending
on its benefit to society ranging from 0.1 mSv for
minor benefit to 10 mSv for moderate benefit,
and > 10 mSv only for substantial benefit [8].
Research studies in healthy volunteers can be
considered of intermediate to moderate benefit,
depending on the type of the study. For each clin-
ical PET occupancy study, the total number of
PET measurements per subject together with
injected radioactivity per PET measurement
should result in a radiation absorbed dose, which
is accepted by the local radiation safety commit-
tee. When PET/CT is used, additional radiation
exposure from CT should be added for the radia-
tion absorbed dose. PET/MRI or digital PET
might help to lead to less radiation exposure in
the future.
c. Availability of human subjects
– Age, gender, healthy volunteers or patients; in gener-
al, dose-occupancy studies are first performed in
healthy subjects, but the findings need to be substan-
tiated in a target patient population.
– In those cases in which it is difficult to perform a
baseline PET measurement, e.g., in cases of drug
naïve patients with schizophrenia, a normal database
can be used as a reasonable alternative for the base-
line measurements. However, this approach should
be considered with caution considering the potential
differences between the two groups of subjects.
d. Characteristics of the radionuclide
– The half-life of the radionuclide (e.g., C-11 or F-18)
used for labelling, defining the minimum interval
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between measurements (at least 5 half-lives) and the
maximum number of PETmeasurements per subject.
– Brain kinetics of the radioligand, defining the
minimum duration of a PET measurement, e.g.,
60 min for [11C]raclopride (dopamine D2 recep-
tor), which requires a radionuclide with a suitable
half-life.
e. Blood sampling and metabolite analysis
– For many PET radioligands (i.e., all radioligands
without a valid reference region), arterial input is
essential for quantitative analysis of occupancy
levels.
Is arterial sampling feasible?
Is the amount of blood to be withdrawn acceptable?
Is equipment for metabolite analysis and measure-
ment of protein binding available?
f. Pharmacokinetics of the test drug
– Safety data, single dose or multiple doses.
– Time to reach the maximum plasma level of the drug.
– Presence of active metabolites
– Timing of pre-treatment PET measurement(s): aimed
for T max and/or T trough? Multiple pretreatment
PET measurements to investigate the time course of
target occupancy.
– Effects of the test drug on cerebral blood flow.
PET measurements should be performed at phys-
iological steady state, i.e., not when cerebral
blood flow undergoes (rapid) changes due to the
test drug.
In some cases, e.g., because of safety issues, only a
limited range of doses of the test drug can be investigated
in a human occupancy study, precluding a full assessment
of the relationship between target occupancy and drug
dose. If occupancies are obtained only at high (i.e.
>95 %) or low (i.e. <10 %) levels, it might be difficult
to assess whether this is due to technical problems in the
quantification of the occupancy or due to the non-optimal
dose selection of the test drug. If preclinical PET occu-
pancy data are available for a wider range of occupancies,
the missing human occupancy data may be extrapolated,
provided the animal data can be extrapolated to the human
situation. In clinical PET occupancy studies, especially
when preclinical PET occupancy data are not available,
the doses of the test drugs should ideally be determined
using an adaptive design. Figure 2 shows an example of a
rather poorly defined dose-occupancy curve, which was
obtained using doses of the test drug that had been fixed
before the start of the PET study. Such an ill-defined dose-
occupancy curve can be avoided by using an adaptive
design.
PET data collection
As for quantitative brain PET studies, dynamic PET measure-
ments are required for an occupancy study. Depending on the
selected (required) quantitative analytical method for the
radioligand, arterial blood sampling, metabolite analysis for the
parent fraction of radioligand and measurement of protein bind-
ing may be needed. After administration of the drug under inves-
tigation, changes in brain kinetics of the radioligand may occur
due to peripheral blocking and/or changes in metabolite profile
and protein binding. When a reference tissue model can be used,
it is important to assess whether the proposed reference tissue can
still be used as reference tissue after administration of the drug. In
case of the pretreatment PET scan, one or more venous blood
samples are taken to measure the plasma concentration of the test
drug. As the plasma concentration of the test drug is expected not
to change toomuch during a PETmeasurement, often the plasma
concentration just before the start of the PET measurement is
used as the actual plasma drug concentration. However, blood
samples at the end of the PET scan should also be collected to
make sure that the plasma drug concentration has not changed
too much and, in some cases, the mean of the plasma concentra-
tions at start and end of a PET scan are used for the pretreatment
plasma drug concentration.
PET data analysis
Calculation of outcome measures for radioligand binding
Calculation of outcome measures for PET occupancy studies
is based on established quantitative methods for individual
Fig. 2 Example of occupancy results following administration of three
different doses of the test drug. In this particular case, drug doses were
fixed prior to the start of the PET study and almost all occupancy values
were close to 100 %, providing little information on the upslope of the
binding curve. This can be avoided by the use of an adaptive design,
where each drug dose is based on the results of the previous
measurement(s)
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radioligands. For a full description of the nomenclature of the
outcome measures used for quantification, see Innis et al. [4].
A general procedure of PET data analysis is as follows.
First, for each individual subject, an MRI scan is acquired.
Next, a summed PET image is generated from the dynamic
PET scan to enable co-registration of PET and MRI images.
After co-registration, the MRI is used to delineate regions of
interest (ROIs). Projecting these ROIs on the (co-registered)
PET scan then generates corresponding time-activity curves.
If studies are performed using a radioligand for which a
region in the brain exists that is devoid of the target being
studied (a so called reference region), reference tissue models
can be used such as the simplified reference tissue model
(SRTM), the Logan non-invasive method, or various
multilinear reference tissue models, depending upon which
method has been validated for the quantification of the
radioligand being used [9–11].
When a radioligand is used for which no reference region
exists, the only option is to perform kinetic analysis using a
metabolite corrected arterial input function. In general, only
VT can be obtained as outcome measure (i.e., including a non-
specific component), as direct estimates of BPND and VS tend
to be less robust (i.e., with large standard errors).
Although in some cases SUVor SUVr have been used as
surrogate outcomemeasures within the context of an occupan-
cy study [12], in general this approach is questionable, as SUV
and to some extent SUVr depend on delivery (plasma curve,
perfusion), which may be affected by the drug. As for any
simplification, this approach can only be used after full vali-
dation against full kinetic analysis.
Automated ROI delineation with or without partial volume
correction can be used for analysing PET occupancy data.
Parametric occupancy images can be generated as well.
However, ROI delineation and partial volume correction
should be exactly the same for both baseline and pretreatment
PET scans.
Calculation of the target occupancy
As mentioned above, in case of radioligands for which a ref-
erence region exists, BPND is the outcome measure. Using
BPND, occupancy Occ can be calculated as follows:
Occ %ð Þ ¼ 100
 BPNDbaselineBPNDdrugÞ =BPNDbaseline;
 ð1Þ
where BPND
baseline is BPND under baseline conditions and
BPND
drug that after administration of the test drug.
In case of radioligands for which no reference region exists,
VT is calculated as outcome measure. However, VT consists of
a specifically bound part (VS) and a nondisplacable part (VND),
Fig. 3 Schematic demonstration of the relationship between the target
occupancy and the dose or plasma concentration of a drug using
dopamine D2 receptor and antipsychotics as example. In case of
dopamine D2 receptor, more than 70 % occupancy is necessary for
clinical efficacy, but extrapyramidal symptoms emerge at more than
80 % occupancy. The dose or plasma concentration to occupy 70–80 %
of the dopamine D2 receptor is considered to be appropriate for the drug
treatment
Fig. 4 Example of eight occupancy data points plotted against the
plasma concentration of the test drug. If the doses of the test drug are
selected appropriately (adaptive design), a wide range of occupancies can
be covered, which would help to select the doses for further clinical trials
Fig. 5 Schematic demonstration of the time course of the target
occupancy and the plasma concentration of a drug using 5HT transport
and antidepressant. The time course of the target occupancy can help to
decide the dosing regimen in addition to the time course of the plasma
concentration of the drug
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which means that occupancy is not directly proportional to the
change in VT. There are several methods to estimate VND, for
example, the method proposed by Lassen et al. [13] in which
VND is derived from the various VT values obtained in a PET
occupancy study. Although this method is easy to apply, it is
important to check whether the underlying assumptions of
identical occupancy levels and VND values across the brain
are still valid for the study.
For radioligands with irreversible binding to the target,
such as [11C]-L-deprenyl-D2 (monoamine oxidase type B
(MAO-B), k3 or λk3 can be used as outcome measure to be
used in Eq. 1 for calculating inhibition (λ =K1/k2) [14, 15].
Estimation of Kd
plasma of the test drug
After occupancy values have been calculated from the PET
measurements, they can be plotted against administered dose
and/or plasma level of the test drug. Based on the Hill equa-
tion [16], the plotted data can be fitted to the following equa-
tion,
Occ %ð Þ ¼ CPdrug= CPdrug þ Kdplasma
   Occmax; ð2Þ
where Occmax represents the maximum occupancy and CP
drug
is the plasma concentration of the test drug or, alternatively,
the dose administered.
Occmax might be fixed to 100 % or estimated based on the
actual data. Kd
plasma corresponds to the plasma concentration
(or dose) at which the target occupancy is 50 %. The equation
was originally based on Kd, which is the dissociation constant
for the local concentration at the target binding. In practice,
Kd
plasma is used as a surrogate of Kd based, assuming that the
two are correlated.
As it is not guaranteed that the relationship between
radioligand and test drug can be described by a Hill equation,
pharmacological information on both radioligand and test
drug should be considered before applying Eq. 2.
PET occupancy studies as a dose selection tool for clinical
trials
The relationship between target occupancy by a drug and its
clinical efficacy and/or presence of side effects has been
established successfully for a limited number of targets, such
as the dopamine D2 receptor and the 5-HT transporter
[17–19]. For example, in case of the dopamine D2 receptor,
approximately 70 % occupancy is necessary for clinical effi-
cacy, but more than 80 % occupancy is related to the extrapy-
ramidal symptoms (Fig. 3) [17]. For new drug targets, such a
relationship should ideally be established in phases 2 and 3 of
the drug development program. Based on the relationship be-
tween test drug’s dose and the target occupancy, as shown in
Fig. 4, several doses of a test drug can be chosen for further
clinical trials, e.g. ,the first dose could correspond with 20 %
target occupancy, the second with 50 % and the third with
80 %. If the appropriate dose to show the clinical efficacy is
not known beforehand, this procedure will provide the most
efficient approach to obtain maximal clinical efficacy together
with minimal side effects. In other words, a PET occupancy
study is an ideal way to select an appropriate drug dose for
further clinical trials. In any case, it provides a means to avoid
selecting too high or too low doses. Finally, by performing
PET measurements at various times after treatment, the time
course of target occupancy can be established, which helps in
the selection of the optimal dosing regimen of the test drug
(Fig. 5) [20, 21].
Finally, as drug development in pharmaceutical companies
is usually performed under tight time constraints, appropriate
PET occupancy study protocols based on these guidelines are
expected to help to speed up the drug development.
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